Cryofocus Medtech (Shanghai) Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Cryofocus Medtech (Shanghai).
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Medical Equipment earnings growth | 40.1% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Is Cryofocus Medtech (Shanghai) (HKG:6922) Using Too Much Debt?
Sep 02
We're Not Very Worried About Cryofocus Medtech (Shanghai)'s (HKG:6922) Cash Burn Rate
Jan 10Cryofocus Medtech (Shanghai) (HKG:6922) Is In A Good Position To Deliver On Growth Plans
Oct 03Companies Like Cryofocus Medtech (Shanghai) (HKG:6922) Are In A Position To Invest In Growth
May 30In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cryofocus Medtech (Shanghai) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 42 | -106 | -103 | -88 | N/A |
| 3/31/2024 | 41 | -102 | -107 | -92 | N/A |
| 12/31/2023 | 41 | -97 | -111 | -96 | N/A |
| 9/30/2023 | 38 | -105 | -116 | -106 | N/A |
| 6/30/2023 | 36 | -113 | -122 | -115 | N/A |
| 3/31/2023 | 31 | -113 | -113 | -106 | N/A |
| 12/31/2022 | 27 | -112 | -104 | -97 | N/A |
| 12/31/2021 | 22 | -102 | -75 | -62 | N/A |
| 12/31/2020 | 9 | -137 | -36 | -34 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 6922's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if 6922's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 6922's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 6922's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 6922's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 6922's Return on Equity is forecast to be high in 3 years time